Search
for
Sort by
Research 151–180 of 198
- Skin, mucosa and nail findings in hospitalized pediatric patients with Coronavirus disease-2019 (COVID-19)
- Ajuga reptans L. Herb Extracts: Phytochemical Composition and Pharmacological Activity Screening
- Mineral Malnutrition Following Bariatric Surgery
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer
- Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers
- Exacerbation of subacute cutaneous lupus erythematosus following vaccination with BNT162b2 mRNA vaccine
- Ruxolitinib protects skin stem cells and maintains skin homeostasis in murine graft-versus-host disease
- Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial
- Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata
- Vitamin D and alopecia areata: possible roles in pathogenesis and potential implications for therapy.
- Health Related Quality of Life of Rosacea Patients in China Assessed by Dermatology Life Quality Index and Willingness to Pay
- Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase‐4 inhibitors
- Health-related quality of life with sacituzumab govitecan in HR+/HER2− metastatic breast cancer in the phase III TROPiCS-02 trial
- Evaluation of platelet-rich plasma on hair regrowth and lesional T-cell cytokine expression in alopecia areata: A randomized observer-blinded, placebo-controlled, split-head pilot study
- Measuring Patient Quality of Life Following Treatment for Alopecia
- Alopecia areata after mogamulizumab treatment
- Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications
- Treatment of alopecia areata with the janus kinase inhibitor upadacitinib: A retrospective cohort study
- Spectrum and Impact of Reported Side Effects of Omalizumab in Patients With Chronic Urticaria: A Long‐Term Multicentre Real‐World Study
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
- A disproportionality analysis of adverse events caused by pexidartinib from the FDA adverse event reporting system
- Alopecia and Periodontitis: Exploring the connecting dots
- The Secrets of Beautiful Hair: Why is it Flexible and Elastic?
- Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study
- Racial and Ethnic Disparities in Persistent Chemotherapy-Induced Alopecia Among Women With Breast Cancer
- Phase II study of safusidenib erbumine in patients with chemotherapy- and radiotherapy-naïve isocitrate dehydrogenase 1-mutated WHO grade 2 gliomas
- Use of oral Janus kinase inhibitors for the treatment of severe alopecia areata: narrative review and real-world experience
- Case Report: Alopecia areata in an adolescent after COVID-19 infection